survodutide vs tirzepatide SURPASS-2 (NEJM 2021) was the definitive head-to-head: semaglutide 1.0 mg (the maximum approved T2DM dose) in 1,879 patients with type 2 diabetes. All three tirzepatide doses produced superior HbA1c reductions Comparison between survodutide, cotadutide, semaglutide,
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14






















